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Readers may have noticed a new 
healthcare catchphrase gracing magazine 
covers and even the front page of the New 
York Times: “personalized medicine.”1 But 
what does it mean and how will it change 
healthcare? According to the President’s 
Council of Advisors on Science and 
Technology, ‘Personalized medicine refers 
to the tailoring of medical treatment to the 
individual characteristics of each patient.’2 
Personalized medicine is important 
because of several emerging clinical and 
financial trends in healthcare. As a result, 
there is a strong impetus for personalized 
medicine, which can succeed if we can 
find a way to break down the silos that 
have traditionally separated clinical and 
financial world views.
The clinical trends important to 
personalized medicine are evidence-
based medicine, the genomic revolution, 
and big data. Evidence-based medicine 
is behind the push to reduce variation in 
care, making providers accountable for 
delivering treatments that are grounded 
in scientific evidence. The genomic 
revolution refers to our ability to quickly 
and cheaply sequence the human genome 
and to determine the biological basis of 
behavior and disease. Big data refers to 
our ability to create large data sets and 
implement automated systems, like IBM’s 
Watson, to sort through and make sense of 
all the information we collect.
Personalized medicine also capitalizes on 
emerging financial trends in healthcare–
pay for performance, bundled payments, 
and expansion of affordable care. Pay for 
performance is where the rubber meets 
the road for evidence based healthcare–no 
outcome, no income. Bundled payments 
refers to the recognition that medical care, 
like a hospitalization for a heart attack, 
should be paid for in a lump sum rather 
than as separate line item bills for the 
hospital stay, EKGs, and aspirin. The need 
to deliver affordable care is at the heart 
of Affordable Care Act, which aims to 
expand health insurance coverage to the 
uninsured by finding savings in other parts 
of the healthcare system. 
Personalized medicine ties together the 
clinical trends of evidence-based medicine, 
the genomic revolution, and big data with 
the financial trends of pay for performance, 
bundled payments, and expansion of 
affordable care. Evidence-based medicine 
gives payers reassurance that individuals 
are getting the most appropriate treatment 
based on published guidelines. Payment 
rates for the expected cost of an entire 
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course of care should be as personalized 
as the treatments they finance, to ensure 
that provider compensation is adequate and 
provides the correct incentives–that will 
require smart bundled payments. Providers 
will collect data on their patients, compare 
outcomes to those in the published 
literature to benchmark their performance, 
and researchers can use the same data to 
refine the published literature on outcomes 
and costs for this population, i.e. big data. 
Payers could use the same data to provide 
extra incentives for high-performance 
care as demonstrated through superior 
outcomes, which is the goal of pay for 
performance. This process will ultimately 
save costs for patients and allow us to 
sustainably cover the entire population 
with health insurance, the essence of 
affordable care.
So what’s the problem? In our current 
fragmented, fee-for-service medical 
system, the vision I outlined has yet to 
become a reality. Personalized medicine 
is a bundled product. However, payers 
often pay for each diagnostic, drug, and 
device separately. We all know that the 
informatics needed to connect a diagnostic 
to the therapy regimen and outcomes 
just doesn’t exist in most healthcare 
environments. Finally, payers are wary 
of the idea of paying more upfront for a 
new technology that promises savings in 
the future—they are more comfortable 
focusing on the cost savings in the here 
and now by denying reimbursement 
for a new test outright, requiring prior 
authorizations, or a high degree of patient 
cost sharing in order to contain costs.
So what’s the solution? Well, we could 
wait for the integrated, affordable 
healthcare system of our dreams. If we 
are talking about today, however, and 
not the year 2100, the answer is to take 
a more integrated perspective. What 
will get payers to agree to pay for a new 
technology when technology has been at 
the heart of our cost containment crisis? 
Data that shows that personalized medicine 
can save costs by avoiding treatments that 
will not work. What will get providers to 
order those tests, and then actually use 
the results? Properly designed incentives 
that compare the expected outcomes 
and costs of care with patients’ actual 
experience. Patients will also need to be 
convinced of the need to become involved 
in personalized treatment decisions. High-
deductible cost sharing and opaque prices 
mean that patients are getting tired of 
being surprised with large bills for care 
that they consider necessary. The promise 
of personalized medicine rests on the 
ability of scientists and financial analysts 
to collaborate to deliver this critical 
information in an impactful way.
I have seen these issues play out on the 
ground level in my own research. In one 
recent study, funded by MDxHealth, 
I was part of a team that investigated 
the potential cost savings from a new 
technology for the problem of unnecessary 
prostate biopsies.3 MDxHealth’s product, 
ConfirmDx for prostate cancer, is designed 
to reduce the cost associated with repeat 
biopsies to diagnose prostate cancer. 
Using a budget impact model, we found 
that there was the potential for the test 
to be cost saving when accounting for 
the costs of repeated biopsies and the 
costs of the side effects of this invasive 
diagnostic procedure. However, the 
potential for cost savings were limited by 
the need to conform to the one-year time 
horizon common in U.S. managed care. 
In addition, prospective trials that collect 
clinical and financial data on the outcomes 
and cost of care will be needed to convince 
payers and providers that our results are 
credible. New payment models are needed 
to correctly align the incentives of patients, 
providers, and payers so that the individual 
responsible for the cost of care shares in 
the benefits of any cost savings.
While there are barriers to studying and 
implementing personalized medicine, the 
underlying forces motivating this new 
platform for healthcare are even stronger. 
The questions of how much technology 
should cost, who should pay, and the 
value of any new technology have taken 
on a heightened significance in the age of 
tighter budgets. Personalized medicine 
holds the promise of moving from a world 
of reducing waste on average to reducing 
waste on a patient-by-patient basis, 
which means a much greater potential for 
savings. In order to realize this vision, it 
will be necessary to collect both clinical 
and financial evidence in order to make the 
case for personalized medicine. We can 
then achieve our goals of treating patients 
as individuals, and doing so at a price we 
can afford. 
Robert D. Lieberthal, PhD 
Assistant Professor 
Jefferson School of Population Health  
Robert.Lieberthal@jefferson.edu
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Health is a personal and intimate experience 
shared through conversations with our 
doctors, family and friends, not merely a 
collection of facts and figures. A discussion 
about shrinking health care costs or expanding 
coverage inevitably leads to a story about 
a great doctor, a bad outcome or a serious 
disease. We have a need to share our pain, our 
fears and our relief about illnesses treated and 
cured. People don’t tell stories about the times 
when nothing happens or goes wrong.
I began my career as a podiatrist specializing 
in the care of the lower-extremity 
complications of diabetes and vascular 
disease. I treated infections and gangrene, and 
often had to cut away dead tissue in the hopes 
of avoiding limb loss. My patients suffered 
from the largely avoidable complications of 
preventable diseases. They were the flesh and 
blood evidence of the failure of a system that 
devotes little of its considerable resources to 
preventing disease—and provides more “sick 
care” than health care. In frustration, I looked 
upstream to find the causes and rediscovered 
public health and population health. I learned 
that many people are trying to rewrite the 
story of health in our nation so that it begins 
with “happily ever after.” More are joining us 
every day as the nation realizes there is not 
enough money in the US Treasury to treat 
every illness that could have been prevented.
Now I teach population health to graduate 
students, most of whom are full-time clinicians 
or other types of health care professionals. For 
many, it’s a hard concept to grasp because they 
are trained to see health through the lens of 
patient encounters. Population health is more 
about what’s not seen, what didn’t happen, 
and persons unknown. It’s about the diseases 
prevented and the complications averted. 
While population health doesn’t make for 
great drama, it is vital to reducing the nation’s 
health care costs and improving our sagging 
health outcomes.
Different -- and most times distinct -- from 
health care is public health, the community-
based system of governmental and non-
governmental organizational policies and 
services that protect us from disease by 
ensuring the water we drink, food we eat, 
the air we breathe, and places we live, work, 
and play are not hazardous to our health. 
Professionals in public health generally 
see the community as their patient because 
people living in healthy communities are 
themselves more likely to be healthy.
As “Obamacare” puts pressure on hospitals 
to improve outcomes, population health 
has become the new buzzword. Non-profit 
hospitals have to justify their charitable tax 
exemptions by documenting community 
benefit, not just financial solvency. All 
hospitals are now judged—and in part 
compensated—by outcomes, such as how 
often patients return with the same condition 
or a related preventable complication. 
Through a variety of carrots and sticks, 
local health care providers and insurers are 
encouraged to address broader community 
needs and to take a more patient-centered 
approach that emphasizes health outcomes 
rather than bottom lines.
Population health bridges the gap 
between health care and public health, 
encompassing key elements of both. 
Health care and public health are viewed 
as separate and distinct systems. The 
professionals in each have limited access 
to, contact with and awareness of each 
other. Opportunities for synergy are often 
missed. Population health is built on the 
premise that health care demand and 
quality is affected by the complementary 
activities of the public health system. 
Conversely, information gathered and 
knowledge gained through the delivery of 
health care services can inform and direct 
more effective public health interventions. 
Population health promotes the ideas that:
•  Our health care system is more likely to 
be efficient and effective when  
fully integrated with community- 
based programs 
•  Patients heal better and faster when 
discharged from the hospital into a 
comprehensive home care system 
•  Hospitals are safer when administrators 
implement systems designed to eliminate 
medical errors and improve outcomes 
•  Health care providers perform better 
when they have access to a patient’s 
complete medical history through a 
comprehensive electronic health record 
•  Health outcomes are improved and 
health care dollars are more wisely spent 
when clinicians base their decisions on 
evidence derived from objective research 
(evidence-based medicine)
•  Our life expectancy and health status, 
and access to care shouldn’t be 
determined by race, ethnicity, gender, 
wealth or zip code
•  All of us benefit when our elected 
representatives enact health policies 
based on sound science.
Health, itself, is difficult to define. Many 
people see it as the mere absence of 
disease—another day without sickness. But 
what about the day before we get sick? Was 
there a moment, an opportunity to prevent 
illness in the first place? Could an ounce of 
prevention save our nation a ton of expensive 
cure? The World Health Organization takes 
this broad view of health by defining it as 
“… a state of complete physical, mental and 
social well-being and not merely the absence 
of disease or infirmity.”1 Population health is 
an effort to achieve this lofty goal. 
Drew Harris, DPM, MPH 
Program Director, Health Policy 
Jefferson School of Population Health 
Drew.Harris@jefferson.edu 
The Untold Story of Population Health
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Preterm birth (PTB), defined as birth before 
37 weeks gestation, is a major population 
health problem. It is the number one cause 
of neonatal morbidity and mortality in 
developed countries--bearing significant 
societal healthcare costs due to short-term 
consequences and complications.1 It is a 
source of concern for policymakers that PTB 
accounts for 12% of all births in the United 
States, a higher rate than other developed 
nations.2 PTB preventative strategies include 
transvaginal ultrasound (TVU) screening and 
progesterone administration.3 Though the 
exact mechanism of action of progesterone 
is not clear, it is thought to provide an anti-
inflammatory effect and counteract the local 
decrease in progesterone levels to decrease 
the likelihood of PTB.
In 2012, the Society for Maternal-
Fetal Medicine (SMFM) published 
recommendations and the American College 
of Obstetricians and Gynecologists (ACOG) 
published an opinion statement relevant to 
progesterone to reduce PTB.4,5 Though a 
number of studies were cited, evidence is 
largely supported by two large trials that 
found vaginal progesterone reduced PTB 
compared to placebo. In 2007, Fonseca et al. 
found that a vaginal progesterone suppository 
(200mg each night) reduced spontaneous 
PTB by 44% (19% vs. 34% in the placebo 
group).6 The PREGNANT trial (The Effect of 
Vaginal Progesterone Administration in the 
Prevention of Preterm Birth in Women With 
a Short Cervix), a more recent randomized 
multi-center trial, demonstrated the efficacy 
and safety of a vaginal progesterone gel 
(90mg daily) in reducing PTB risk and 
associated neonatal complications. Results 
indicated that the vaginal progesterone gel 
was associated with a 45% reduction in PTB 
before 33 weeks (9% treatment vs. 16% 
control) and was associated with a 43% 
significant reduction in composite neonatal 
morbidity and mortality (8% treatment vs. 
14% control).7
The evolving evidence regarding 
progesterone has stimulated controversy 
as to whether all pregnant women should 
receive a TVU screening to detect short 
cervix (i.e., universal screening), as opposed 
to screening only women determined by 
their physician to be at high risk for PTB. 
Since high risk is typically defined based on 
history of prior PTB, screening only these 
women would leave out two major cohorts 
of the pregnant population: 1) those who are 
pregnant for the first time and have a short 
cervix, and 2) those who have a short cervix 
despite history of full-term pregnancies. 
Proponents of universal screening argue that 
it makes sense to support this strategy since 
evidence supports the benefit of progesterone 
in women found to have short cervix.4  On 
the other hand, opponents of universal 
screening contend that: 1) there is a lack of 
efficacy data specifically on the strategy of 
universal TVU screening followed by vaginal 
progesterone; 2) the implementation of 
proper TVU screening technique is required 
in order to ensure accurate results; 3) certain 
geographic areas lack sufficient availability 
of TVU screening; 4) in certain women, 
short cervix can be identified without TVU; 
and 5) there is the possibility of differing 
results when TVU screening is completed in 
practice versus within a clinical trial.4 SMFM 
recommendations state that, though there 
is currently insufficient evidence to support 
universal screening, it is a reasonable practice 
for individual physicians to choose. 
In summary, while many clinicians currently 
support a strategy of universal TVU screening 
followed by progesterone in women 
detected to have short cervix, this remains an 
acceptable but controversial practice. Until 
more evidence is available, the issue will 
persist as a topic of clinical debate.  
Elizabeth Mearns  
Doctor of Pharmacy Student1 
Laura T. Pizzi, PharmD, MPH1 
Jason K. Baxter, MD, MSCP2 
Vincenzo Berghella, MD2
1  Jefferson School of Pharmacy, Thomas 
Jefferson University, Philadelphia, PA 
2  Division of Maternal-Fetal Medicine, 
Department of Obstetrics and Gynecology, 
Jefferson Medical College of Thomas 
Jefferson University, Philadelphia, PA 
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JSPH Graduate Certificate in Population Health 
The paradigm has shifted.  The current health system is broken. 
We are moving to a new model that stresses population health. 
Jefferson’s Graduate Certificate in Population Health is 
intended for current and emerging leaders who want to thrive under Health 
Reform and implement real world solutions. 
• 5 online courses (15 credits)
• 21 months to complete
• $725 per credit
The Certificate will enable you to:
1. Define the population health paradigm and its relationship to the chronic care model.
2. Describe ways in which a population health perspective reorders existing healthcare 
priorities and establishes new priorities in areas such as prevention, evidence-based 
practice, comparative effectiveness, public health and health policy.
3. Identify and address key determinants of population health outcomes.  
4. Identify and characterize key stakeholders, including governmental and private 
sector institutions, and analyze how their complex relationships influence 
population health outcomes. 
5. Analyze the impact of health care and health services on population health outcomes 
and identify strategies for improving healthcare quality and safety.
6. Analyze the relationship of population health outcomes to health economics 
and to value in health care. 
Curriculum
• Population Health and Its Management
• U.S. Healthcare Organization and Delivery
• Introduction to Healthcare Quality and Safety
• Chronic Illness Prevention and Chronic Care Management
• Introduction to Health Economics and Outcomes Research
Admissions Considerations
• Bachelor’s degree with GPA of 3.0
• GRE or other graduate entrance exam or graduate degree or 9 graduate credits
For more information: Samia.White@jefferson.edu or 215-503-0174
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Vaccines rank among the top ten public 
health achievements of the past century, 
along with food safety, control of infectious 
diseases, healthier mothers and babies, 
automobile safety, fluoridation of drinking 
water, family planning and others. The 
sad irony is that our success in eradicating 
scourges like smallpox, polio and diphtheria 
is threatened by unfounded fears regarding 
vaccine complications. Across the nation, 
the public health community is confronting 
a backlash against state vaccination 
requirements spearheaded by small but vocal 
groups of anti-vaccine activists concerned 
about vaccine safety and issues of personal 
choice.1 In New Jersey’s case, legislation to 
tighten religious exemption regulations is the 
current focal point for their lobbying efforts.
Mandatory childhood vaccination was 
a key element in our success in the 
war against deadly infectious diseases. 
Voluntary efforts do not ensure enough 
children are vaccinated to prevent efficient 
person-to-person transmission of vaccine-
preventable disease—often called “herd 
immunity.” Without susceptible people to 
infect, infectious agents hit a dead end and 
the disease outbreak ultimately dies out. 
Children are at higher risk for these diseases 
and are more likely to spread it to vulnerable 
populations such as infants, immuno-
compromised people and the elderly.
Every state in the nation has a law requiring 
school children to be vaccinated against 
serious illness such as measles, mumps, 
rubella, polio and others. All states exempt 
individuals with medical conditions that 
put them at risk for complications from 
the vaccine, and all but two states provide 
for religious exemptions. Nineteen states 
allow parents to opt their children out of 
the vaccines over philosophic or moral 
concerns.2 States that only require a simple 
statement of objection, rather than a more 
rigorous exemption process, are seeing a 
significant increase in outbreaks of vaccine-
preventable disease.3, 4, 5
This controversy is not new. In 1902, 
Henning Jacobson refused an order of 
the Cambridge, Massachusetts Board of 
Health requiring him to take a smallpox 
vaccination, claiming that the requirement 
violated his personal liberty. He was fined 
$5 as a result. He appealed his case to the 
US Supreme Court, which sided with the 
Board saying that the “…community has 
the right to protect itself against an epidemic 
of disease.”6 Jacobson v. Massachusetts 
became the seminal case codifying the 
principle that community wellbeing can 
trump individual liberty and that public 
health agencies have the authority to impose 
these requirements. 
In its decision, the Supreme Court allowed for 
medical exemptions, but denied exemptions 
for religious or philosophic beliefs. The 
courts have generally held in other cases 
that the religious freedoms guaranteed by 
the First Amendment can be curtailed, when 
necessary, to protect public health.7 
States are not constitutionally required to 
grant religious exemptions, but when they 
do the procedure by which exemptions are 
granted must comport with the Constitution. 
For example, the government cannot require 
proof of membership or regular attendance 
at services of an “established” religion 
before granting an exemption. To do so 
would run afoul of the First Amendment 
prohibition against the government 
establishing a religion. However, it can 
require proof of the sincerity of one’s 
religious belief; applying the principles used 
to assess the veracity of the conscientious 
objectors to required military service. No 
conversions are allowed on the way to the 
draft board.
It is this issue of the nature of the religious 
objection against the vaccination mandate 
that is in question in New Jersey. State law 
mandates that parents provide proof of a 
child’s appropriate immunization against 
a variety of diseases prior to attendance 
at daycare, school or college.8 The law 
leaves enforcement to local public health 
and school officials. Standards for granting 
exemptions have varied across jurisdictions 
and some officials may have been requiring 
proof of church membership rather than 
examining the sincerity of the beliefs.8 
In response to a request for guidance from 
local officials, the New Jersey Department of 
Health and Office of Attorney General issued 
interim policies and ultimately regulations 
that said no inquiry into the nature of a 
family’s religious belief could be made 
before granting an exemption.8 All that could 
be required was a written statement from 
the parents that included the word “religion” 
or “religious.” Officials could not inquire 
how long the belief was held; whether the 
child received some but not all vaccines, or 
if other family members were vaccinated; 
if their primary concern was the safety of 
the vaccine; or if they would vaccinate 
against the disease if it presented itself in the 
community. In essence, anyone could claim 
a religious exemption for reasons that had 
nothing to do with religion.
A preliminary analysis of school 
immunization reports revealed that the 
number of students with active religious 
exemptions statewide went from 1,625 
in 2007, prior to the change in standards, 
to 6,204 in 2011 or 1.2% of the sampled 
population (Harris: unpublished data). 
While it can’t be proven that the 
regulatory change allowed for more 
religious exemptions, anecdotally there 
was evidence (via online forums) that 
parents whose objections to vaccinations 
were more philosophic or safety-related 
were exchanging tips on how to obtain an 
exemption based on religious objection.
These new regulations effectively 
converted New Jersey’s current law limiting 
vaccine mandate exemptions to medical 
or religious grounds into a law allowing 
liberal philosophic exemptions. The data 
supported the concern that the number of 
under-immunized children was quickly 
approaching a level similar to states with lax 
philosophical exemption standards, putting 
the state at risk of major outbreaks.
The New Jersey state legislature is 
considering a bill (S 1759)9 that will make 
New Jersey Vaccine Mandates: The Confluence of Regulations, 
Rights, and Religion
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explicit the process for granting religious 
exemptions and follow judicial precedent 
allowing for appropriate verification 
of religious exemption claims. Recent 
outbreaks of pertussis10,11 and mumps 
are just a foreshadowing of what might 
be coming if the state continues to allow 
parents unqualified access to the religious 
exemption process. 
Immunity against vaccine-preventable 
disease is a community resource, 
bequeathed to us by generations past and 
current who rolled up their sleeves for 
shots that protected not only themselves but 
everyone else. 
Drew Harris, DPM, MPH  
Program Director, Health Policy 
Jefferson School of Population Health 
Drew.Harris@jefferson.edu 
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It was Bernard Wolfman’s love of words 
that inspired the creation of the Bernard 
Wolfman Civil Discourse project, and 
the inaugural Civil Discourse on the 
topic of the role of government in health 
reform. On March 28, 2013, the fourth 
night of the Jewish Passover, David 
Nash, MD, MBA and Stuart Butler, PhD, 
drew a crowd of over five hundred to 
Beth Shalom Congregation in Elkins 
Park, Pennsylvania, where they engaged 
in a public conversation moderated by 
Chris Satullo, WHYY vice president for 
news and civic dialogue, and co-founder 
and co-director of the Penn Project for 
Civic Engagement at the University of 
Pennsylvania. Distinguishing between civil 
discourse and talk-show debate, Satullo 
defined civil discourse as an ‘exploration’ 
of ‘shared identities’ and leveraging 
‘intellectual and ideological diversity to 
model a means to generate effective public 
policy.’ The two candidates agreed not 
to argue or debate, despite their differing 
views on government’s role in health care. 
Stuart Butler, PhD is currently serving 
as Director of the Center for Policy 
Innovation at The Heritage Foundation, 
a conservative think tank located in 
Washington, DC. An expert in the areas 
of Medicare, entitlements, and health 
care reform, Butler identified three main 
influences on his political views: the ethics 
and values of Judaism, the principles of 
market economics, and the principles of 
federalism. He went on to ask although 
the general consensus is that Americans 
ought to have ‘equitable, affordable care,’ 
what level and how much health care 
should Americans expect? He expressed 
his concern over what he views as a 
‘spend then bill’ system, which lacks a 
concrete budget. A staggering hypothetical 
statistic supported Butler’s concerns: if 
the United States’ health care system were 
its own economy, it would be the sixth 
largest economy worldwide, surpassing 
both France and Britain. Butler also 
expressed his specific concern over the 
recently passed Affordable Care Act; “If 
government cannot organize a system of 
records, can government come in to the 
exam room?”
David Nash, MD, MBA, Dean of Jefferson 
School of Population Health and a 
practicing internist, emphasized right away 
the need for eliminating waste in our health 
care system. Nash identified six areas of 
waste: overtreatment, failure to coordinate 
care and the lack of follow up, failure in 
execution, administrative failure, pricing 
failure, and fraud/abuse, the elimination 
of which would allow the US to fix its 
broken system. Nash also supplied his own 
hypothetical statistic; with medical errors 
currently the fourth leading cause of death 
in this country, it is akin to a 747 crashing 
every day, killing all its passengers. He went 
on to express his continued outrage that 
this persists, “What other industry would 
tolerate this?” Nash agreed with Butler’s 
observation that healthcare spending is out 
of control in this country, at 20% of the 
gross domestic product, but disagreed with 
Butler, remarking that ‘only Uncle Sam has 
the power to rein in spending, change the 
payment process to reduce waste.’
While they differed in their perspectives 
of the government’s role in health care, the 
The Bernard Wolfman Civil Discourse Forum
Beth Shalom Congregation
March 28, 2013
Above: David Nash, MD, MBA (left) and Stuart Butler, PhD. (right). 
Above: David Nash (top); Stuart Butler 
(left) and Chris Satullo (right).
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two experts did converge on a number of 
details. When asked about the idea that 
most healthcare spending comes about 
in the last two years of life, both Butler 
and Nash agreed that Americans need to 
start having more conversations with their 
loved ones and their providers about end 
of life. Dr. Nash went a step further to say 
that one way to ensure this conversation 
takes place would be to create a Medicare 
fee for the end of life conversation. Ever 
the educator, he also indicated that this 
is a huge opportunity for an educational 
piece. Both speakers also agreed on the 
importance of care coordination and 
accountability on the part of both patient 
and provider. 
When asked by Satullo about the 
implementation of a single payer system 
in the United States, both experts said 
that they didn’t believe it would work, 
and each offered a humorous explanation 
of why. Butler gave a nod to his British 
roots when he said “British people see a 
line, they get in it, and then ask what it’s 
for.” Americans will not wait for health 
care. He also expressed his concern that 
if implemented, a single payer system 
might eliminate the worry of being 
bankrupted by medical bills at the expense 
of not receiving medical care at all. He 
ended by saying that healthcare requires 
flexibility, and the federal government 
cannot be flexible. Nash weighed in on 
implementing a single payer system by 
stating, “I like my Lipitor on the way to 
McDonalds. I want you to buy the Lipitor, 
and I’ll buy the Big Mac.” Nash offered 
advice to fix the broken system in the form 
of a seven point plan: a greater level of 
patient engagement, including an open 
medical record; simply asking caregivers 
if they have washed their hands; the 
Choosing Wisely campaign; encouraging 
end-of-life conversations; behavioral 
modifications such as exercise, wearing 
seatbelts, and stopping smoking; finding 
a primary care doctor and visiting that 
doctor: and finally, practicing charity.
Though the evening ended without 
a “debate winner” guests were left 
with evidentiary proof that a civil 
conversation between adversaries can 
lead to convergences and opportunities 
to work toward common goals. The 
Project’s namesake, who treasured his 
Oxford Dictionary and his Merck Manual 
of Medical Information, believed in 
maintaining respect in a disagreement, a 
principle upheld by both speakers. 
Kate Cecil, MS 
Project Manager  
Jefferson School of Population Health  
Kate.Cecil@jefferson.edu
The Jefferson School of Population Health 
(JSPH) has award the Joseph S. Gonnella, 
MD Scholarship to Evan Bilheimer, a 
Jefferson Medical College (JMC) student 
who recently completed his third year of 
medical school and is entering the MPH 
program at JSPH.  He received high 
honors in Neurology and Pediatrics in Fall 
2013 and he participates in the College 
within a College, Population Health 
voluntary scholarly concentration. 
The Joseph S. Gonnella Scholarship 
is named in honor of Dr. Gonnella, 
Distinguished Professor of Medicine, 
former Dean of Jefferson Medical College, 
and founder and director of JMC’s Center 
for Research in Medical Education and 
Healthcare. This merit-based award is 
intended specifically for highly qualified 
students of JMC who wish to pursue an 
MPH in addition to their medical degree. 
Bilheimer graduated from the University 
of Rochester in 2009, Magna Cum Laude, 
with degrees in History and Chemistry. 
During his time in undergraduate school, 
Bilheimer volunteered for two medical 
service trips abroad for Shoulder to 
Shoulder, Inc.  After graduation, he 
worked for AmeriCorps as an HIV 
Counselor and Teen Substance Abuse 
Youth Group Leader at the Massachusetts 
League of Community Health Centers, 
Neponset Health Center in Dorchester, 
Massachusetts.   
Since entering medical school, he 
participated in the Bridging the 
Gaps Community Health Internship 
program providing health education 
and programming at To Our Children’s 
Future with Health, a community-based 
non-profit agency.  Bilheimer has also 
volunteered with JeffHOPE and the 
Refugee Health Partner’s Houston Clinic.  
Bilheimer intends to pursue a career in 
Family Medicine by providing preventive 
community health services and becoming 
involved in the administration and delivery 
of healthcare at the systems level.  He 
believes the MPH program will equip him 
with skills for evaluating and managing 
the various social determinants of health, 
while becoming actively involved with 
the changing health care environment and 
practice transformation. He is committed to 
providing equitable and quality healthcare 
to patients and populations. 
Joseph S. Gonnella, MD Scholarship Awarded to Evan Bilheimer
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Nine representatives from Thomas Jefferson 
University, including two from the Jefferson 
School of Population Health (JSPH), 
attended the fourth annual conference of 
the Consortium of Universities for Global 
Health in Washington, DC (March 14-16, 
2013). The theme was Global Health: 
Innovation/Implementation/Impact. The 
program featured world-renowned keynote 
speakers and plenary panels addressing 
the complexity of today’s global health 
challenges and highlighting a diverse group 
of experts from a broad range of sectors. 
It was clear that solving global health 
problems requires a collaborative approach 
that harnesses the skills and energies of 
multiple disciplines, promotes cooperation 
across multiple sectors and embraces 
innovation. Over 1,390 people attended 
the conference, representing more than 56 
countries. More than 230 speakers presented 
in the concurrent and special sessions and 
308 posters were on view; two of the posters 
were from the JSPH. A third of the posters 
focused on education and capacity building 
in global health.
The conference began and ended with 
inspiring presentations from the very 
dynamic Agnes Binagwaho, MD, M(Ped), 
Minister of Health, Rwanda. Plenaries 
addressed the issues of: Global leaders in 
global health; US Government Agencies 
for Global Health; Innovative financing 
mechanisms for global health; Innovative 
technologies and approaches for global 
health: transforming the present and future; 
Global health justice: Empowering women, 
catalyzing change; and Climate change 
and global health: using science to protect 
populations. The four prominent directors 
of US Government Agencies for Global 
Health were particularly impressive: Francis 
Collins, MD, PhD, Director National 
Institutes of Health (NIH); Thomas Frieden, 
MD, MPH, Director, Centers for Disease 
Control and Prevention (CDC); Eric Goosby, 
MD, US Global AIDS Coordinator, Office 
of Global Health Diplomacy; and Jonathan 
Woodson, MD, Assistant Secretary of 
Defense (Health Affairs) and Director 
of TRICARE Management Activity, US 
Department of Defense. 
Special sessions on the Role of NIH in 
Global Health Research, Crisis in the 
Sahel and the Global Burden of Disease 
(GBD): 2010 Report1 were both timely 
and informative. The session on the Global 
Burden of Disease by Christopher Murray, 
MD, DPhil, Director, Institute for Health 
Metrics and Evaluation used innovative 
technology to present the GBD report 
which facilitates comparisons across a 
multitude of mortality, morbidity, and 
quality of life indicators on 291 diseases 
and injuries, 67 risk factors, and over 1000 
sequellae from 186 countries2 and was 
truly amazing. 
The concurrent sessions covered a very 
broad range of topics and disciplines. 
Topics included: mHealth, oral health, 
OneHealth, community health, scaling 
for impact, climate change, human rights, 
primary health care, women’s health, global 
local health, social media. Key themes that 
ran throughout include: the importance of 
collaborating with China and Latin America; 
developing a sustainable health work force; 
partnering with faith-based organizations 
and the private sector; and creating cross-
discipline approaches to address malaria and 
neglected tropical diseases. 
Overall, some of the key themes and take 
away messages of this conference were 
focused on: 
•  Innovation (i.e. mHealth, eHealth, 
telemedicine, technology) as the means 
of communication, analysis, and 
treatment for the future. 
•  Global health programs are also local or 
“glocal” problems.
•  Research and sharing research findings 
with subjects of research is key to policy. 
development and targeted programs. 
Resolving global health issues requires a 
collaborative cross-cutting approach that 
encompasses multiple disciplines, promotes 
cooperation, and embraces innovation. 
The Jefferson team has been meeting in an 
attempt to capture the best from the CUGH 
conference to apply it to the improvement of 
the TJU global health education programs. 
Lucille B. Pilling, EdD, MPH, BSN, RN 
Lecturer, Global Health, Jefferson School 
of Population Health  
Adjunct, Assistant Professor of Nursing, 
University of Pennsylvania School of Nursing 
Lucille.Pilling@jefferson.edu
Rob Simmons, DrPH, MPH,  
MCHES, CPH 
Associate Professor  
Program Director, Public Health, Jefferson 
School of Population Health  
Rob.Simmons@jefferson.edu 
 
For more information on this conference 
visit: http://2013globalhealth.org/
Global Health: Innovation/ Implementation / Impact
A report on the Fourth Annual Conference of the Consortium of Universities for Global 
Health (CUGH)
REFERENCES
1.  The global burden of disease study 2010. The Lancet. Published December 13, 2013. http://www.thelancet.com/themed/global-burden-of-disease. Accessed April 5, 2013. 
2.  Institute for Health Metrics and Evaluation. GB Compare Tutorial. 2013. http://www.healthmetricsandevaluation.org/gbd/multimedia/video/gbd-compare-tutorial. 
Accessed April 24, 2013. 
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Although social work and public health share historical roots, their paths have diverged until recently. Today’s complex health issues 
require the expertise of both professions. This year’s Public Health Week symposium and luncheon explored the intersections among 
public health, social services, health care and policy.   Moderated by Dr. Bailey, Dean and Professor of the Graduate School of Social 
Work and Social Research at Bryn Mawr College, the panelists discussed the importance of a multidisciplinary perspective on health; 
implications of social work and public health principles for health and well-being; and the need for cross-disciplinary collaborations.  
The Jefferson School of Population Health and the Bryn Mawr College of Graduate School of Social Work and Social Research 
(GSSWSR) have partnered to offer dual degrees in social work (Master of Social Service – MSS) and public health (Master of Public 
Health – MPH). For more information about this exciting dual degree program, visit:  
http://www.jefferson.edu/population_health/academic_programs/dual_degrees/mss-mph-dual-degree-program.html 
Panelists from left to right: Christina Miller, MSS; Jennifer Campbell, PhD; Cindy Sousa, PhD, MSW, MPH; Joanne Fisher, MSS, and 
Darlyne Bailey, PhD, LISW 
National Public Health Week
Meeting Again at the Crossroads: Social Work and Public Health
April 4, 2013
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The Department of Emergency Medicine 
at the Thomas Jefferson University has 
offered a two-year Fellowship in Global 
Health since 2011. Fellows work part-time 
as attending physicians in the Emergency 
Department, and study towards a Master 
of Public Health degree at the Jefferson 
School of Population Health, while 
spending three months per year doing 
fieldwork. As our department’s first Global 
Health Fellow, I volunteered (May - 
August 2012) with a non-governmental 
organization called International Medical 
Corps (IMC) in the East-African nation of 
South Sudan. 
South Sudan seceded from Sudan in July 
2011 to become the world’s youngest 
nation. The country was wracked by 
almost 60 years of civil war, leaving 
the South one of the most undeveloped 
countries in the world and with some of the 
poorest economic and health indicators in 
all of Africa. It has less than 200 miles of 
paved roads, only 16% of the population 
has access to healthcare of any kind, and 
for every 100,000 births over 2,000 women 
die from the complications of delivery.
IMC has had aid and development 
programs in many parts of South Sudan 
prior to its secession from the North. One 
of their most long-standing programs is 
in Akobo County on the eastern border 
of country. Akobo has no paved roads 
and heavy rains turn large swaths of the 
county into impassable swamps for almost 
nine months out of the year. The standing 
water is a perfect breeding ground for 
mosquitoes that carry malaria and the thick 
mud makes walking just a few hundred 
meters an energy-sapping slog.
The people of Akobo mostly come from 
one of two tribes that have a long-standing 
history of deadly conflict between them: 
the LuoNuer and the Murle. Both tribes 
live in tukuls (mud and straw huts) and 
survive off of a combination of subsistence 
agriculture, fishing, and raising cattle and 
goats. A custom the tribes have in common 
is that they use cattle as dowry; a man must 
give a woman’s father roughly 20 cows to 
secure her hand in marriage. This need for 
cattle has led the two tribes to carry out 
raids on each other’s herds. Cattle raiding, 
combined with a history of conflict between 
the tribes, has resulted in deadly and 
ongoing violence that has only worsened 
with the introduction of automatic weapons 
during the long civil war.
IMC operates the Akobo County Hospital – 
the only hospital for hundreds of kilometers 
in every direction. IMC employs one doctor 
at the hospital; the remainder of the medical 
staff there is composed of community health 
workers, clinical officers, and assistant 
nurses. Staff have had anywhere from three 
months to two years of medical training. 
While they are hardworking and dedicated 
to their community, I found that many 
of them had extremely limited reading, 
writing, and math skills, which sometimes 
led to errors such as incorrect medication 
dosages or administration.
I worked on an IMC project funded by the 
UN’s Common Humanitarian Fund and 
the European Community Humanitarian 
Office to improve care for traumatically 
injured patients in Akobo County. People 
in Akobo may suffer trauma due to falls 
or farming accidents, but the majority of 
serious trauma is due to gunshot wounds 
or stabbings that occur during inter-tribal 
conflicts. Working with IMC employees 
and volunteers, I developed a curriculum 
to teach hospital medical staff and lay 
community members skills and concepts 
that are important to treating trauma 
victims. Some of the topics we covered 
included mass casualty triage, stabilization 
of bleeding or burned patients, and 
splinting of broken bones.
Curriculum development proved to be 
especially challenging in this environment. 
For one, the majority of the people we 
were targeting for training did not speak 
English and were not literate. We also 
had no reliable source of electricity, so 
the lectures and training sessions had to 
be given using only a dry-erase board 
and some printed diagrams. Additionally, 
medical resources at the hospital were very 
limited so the material had to be closely 
tailored to what was on-hand; x-rays were 
not available so we did not discuss x-rays. 
To overcome some of these challenges we 
made use of local interpreters and used 
simulations to teach clinical principles.
During this global health project I learned 
firsthand about some of the challenges 
of developing and implementing a health 
education program. These experiences will 
help guide me during future public health 
projects. The project in Akobo is ongoing 
and a new set of IMC employees and 
volunteers is currently in Akobo County. 
There is some hope for South Sudan overall 
as the conflict over oil production with 
Sudan is being gradually resolved. 
Masashi Rotte, MD 
Assistant Professor and Fellow in  
Global Health  
Department of Emergency Medicine 
Thomas Jefferson University  
MPH candidate, Jefferson School of 
Population Health 
For more information on the Global Health 
Fellowship contact Dr. Harsh Sule at 
Harsh.Sule@jefferson.edu.
Global Health in the World’s Youngest Nation
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As healthcare expenditures continue to 
rise, stakeholders across the healthcare 
system are searching for ways to improve 
the quality of care and optimize the use of 
resources. Achieving these goals requires 
engaging and educating each participant 
– patient, payer, and provider – so they 
can better understand the issues and work 
together toward meaningful solutions. 
The Patient Protection and Affordable 
Care Act has led to the introduction of 
several new initiatives aimed at increasing 
accountability for outcomes and delivering 
a higher return on healthcare expenditures. 
To help all stakeholders understand 
and adapt to this transition, JSPH has 
developed a live educational series focused 
on quality and safety leadership. The 
faculty for this program is drawn from 
among some of the top experts in the field 
from across the country.
The Quality and Leadership Series (QSLS) 
is a live series of customized educational 
programs designed to meet the unique 
needs of healthcare professionals, whether 
they have clinical or administrative 
responsibilities. Through the generous 
support of Sanofi US, JSPH developed 
this series to connect some of the 
nation’s foremost experts to healthcare 
professionals across the country. 
Programs are geared toward institutions 
and professional associations seeking to 
learn how to improve the quality and safety 
of healthcare delivery. Content is adapted 
for each program to meet the unique needs 
of each audience and organization that 
requests a program. There is no cost to 
the requesting organization; JSPH simply 
requests that all attendees complete a post-
program evaluation.
JSPH maintains a catalog of faculty and 
topics, available at http://www.jefferson.edu/
qsls. QSLS program staff work to identify 
appropriate faculty based on the information 
submitted, and work closely to facilitate 
program planning between the speakers and 
the requesting organization. 
For more information or to request a QSLS 
program, visit http://www.jefferson.edu/
qsls for a request form that can be sent via 
e-mail to QSLS staff at qsls@jefferson.edu. 
You may also contact us by phone at  
(877) 662-7757. 
The Quality and Safety Leadership Series
JSPH has recently launched a live series of educational programs focused on quality and safety. 
Practice Improvement Strategies:  
Online CME Opportunity 
The Jefferson School of Population Health is establishing exciting new partnerships to enhance professional development and CME 
opportunities that are directly relevant to clinical practice in this changing healthcare landscape.  A recent collaboration, The Johns 
Hopkins University Practice Improvement Strategies in Cardiometabolic Disease Therapies, presents a complimentary PI-
CME activity that provides primary care physicians, endocrinologists, cardiologists, NPs and PAs with the tools to measure quality 
of care and to identify opportunities to improve the outcomes for their patients with cardiometabolic disease.  
All practicing clinicians can earn 20 CME/CE credits without the need to attend a live or online program.  After collecting some 
basic data on their patients, participants will be provided with benchmarking reports that satisfy American Board of Internal Medicine 
(ABIM) MOC Part IV requirements.  Participants will also receive detailed clinical reports analyzing care delivered to patients with 
cardiometabolic disease against individual peers (anonymously) and national trends.  The program will also provide exclusive access to 
a secure and moderated “mentor program,” an online Q&A forum with nationally-recognized experts in the field.
Clinicians are invited to share the benefits of the educational grant funding that supports this program.  Each participating practice 
is eligible to receive $500 to support the collection of data on 25 patients with diabetes, hypertension, dyslipidemia and/or obesity.  
Funds are limited and will be awarded on a “first come, first served” basis.  Interested practices are encouraged to complete a brief 
registration online at http://jhucardio.imedicaldecisions.com, or to contact us by email at PIsupport@imedicaldecisions.com, or to 
call (610) 891-1640.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to 
provide continuing medical education for physicians.
The Johns Hopkins University School of Medicine designates this PI CME activity for a maximum of 20.0 AMA PRA Category 1 
Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
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Have you ever received unnecessary care? 
This is how Mr. Wolfson, Executive Vice 
President and Chief Operating Officer of 
the ABIM (American Board of Internal 
Medicine) Foundation initiated the 
discussion on “overuse” in healthcare. 
The ABIM Foundation is a not-for-profit 
organization focused on advancing medical 
professionalism and physician leadership to 
improve the health care. 
Wolfson described overuse as unnecessary 
procedures where the benefits don’t exceed 
the risks. The problem of overuse and 
overtreatment is staggering in the US. 
Wolfson explained that over $200 billion 
per year is wasted on overtreatment. 
The Choosing Wisely® campaign of the 
ABIM Foundation is an initiative that 
is aimed addressing this problem by 
helping physicians and patients engage in 
conversations about the overuse of tests and 
procedures, and support physician efforts 
to help patients make smart and effective 
care choices. The major components 
of the campaign include: simplicity, 
unexpectedness, concreteness, credibility, 
emotions, and stories. Wolfson shared his 
own personal stories to illustrate the classic 
examples of overtreatment. 
An important component of the Choosing 
Wisely® Campaign is the document, Five 
Things Physicians and Patients Should 
Question, a series of lists representing 25 
specialty societies in the US. By recognizing 
the significance of patient and provider 
conversations, the tool is aimed at improving 
care and eliminating overtreatment. The 
comprehensive lists include scientific, 
evidence-based recommendations to help 
make decisions about the most appropriate 
care. Consumer Reports, a partner of 
Choosing Wisely,® has produced over 
35 patient-friendly materials based on 
medical society recommendations that will 
disseminate information about appropriate 
use of medical tests and procedures. 
Wolfson explained that the success of the 
campaign is based on intrinsic motivation 
and a shift in cultural attitude. For example, 
the emphasis should be on “why”: “Why did 
you need that procedure or test?” rather than 
“Why didn’t you do that procedure or test?”
The campaign will continue to grow 
and flourish as it galvanizes multiple 
stakeholders (i.e. office practices, residency 
and medical training programs, health 
systems) to advance the campaign. 
To learn more about the Choosing  
Wisely® Campaign visit:  
http://www.choosingwisely.org/
To read Mr. Wolfson’s Medical 
Professionalism Blog visit: http://blog.
abimfoundation.org/about_our_authors/
Population Health Forums
The Choosing Wisely® Campaign: Is This a Game Changer? 
Daniel B. Wolfson, MHSA  
Executive Vice President and Chief Operating Officer  
American Board of Internal Medicine Foundation 
January 9, 2013 
New Therapeutic Options for Stroke Prevention in Atrial Fibrillation 
Joseph D. Jackson, PhD 
Program Director, Applied Health Economics and Outcomes Research  
Jefferson School of Population Health 
February 13, 2013 
Anti-coagulation therapy for stroke 
prevention in Atrial Fibrillation (AF) has 
been dominated by the drug warfarin for 
more than 50 years, yet three recently 
approved drugs are viable therapeutic 
alternatives to warfarin. However, according 
to Dr. Jackson, Program Director for Applied 
Health Economics and Outcomes Research 
at JSPH, they are not without challenges to 
optimize care for AF patients. He helped 
provide a clear and insightful overview of 
this topic at a recent Forum. Dr. Jackson 
has over 30 years of experience in the 
pharmaceutical industry, with much of this 
time devoted to clinical research and the 
management and practice of Outcomes 
Research, including the transition of 
clinical evidence into user-friendly cost-
effectiveness models. 
The framework for Dr. Jackson’s presentation 
was based on outcomes research, which 
he described as the “study that studies the 
studies.” The purpose of outcomes research, 
according to the Agency for Healthcare 
Research and Quality (AHRQ), is to examine 
three questions: 1) Do patients benefit? 2) 
What treatments work best? And, 3) Are 
health-care resources well spent? 
Jackson first cited the incidence of AF 
by explaining that approximately 15% of 
all strokes occur in people with AF; the 
risk of stroke in patients with untreated 
AF averages 5% per year and increases 
with advancing age. Jackson emphasized 
the chronic and devastating nature of AF 
and the importance of understanding the 
efficacy and the effectiveness in the real 
world of therapeutic options. 
For many years, warfarin has been the 
only oral anti-coagulant available for 
chronic care. Though hugely successful in 
terms of stroke prevention, its use presents 
Continued on page 16
16   |   POPULATION HEALTH MATTERS
Moving The Needle: Challenges and Opportunities in Communicating Patient-Centered 
Outcomes Research 
Bill Silberg  
Director of Communications  
Patient-Centered Outcomes Research Institute (PCORI)
March 20, 2013 
The Patient-Centered Outcomes Research 
Institute (PCORI) is an independent 
non-profit research organization charged 
with the task of helping the public make 
informed decisions and improving health 
care delivery and outcomes by producing 
high-quality evidence-based research. 
PCORI was authorized by Congress as 
part of the 2010 Patient Protection and 
Affordable Care Act (ACA). Bill Silberg, 
Director of Communications at PCORI, 
shared an insightful overview of PCORI’s 
mission and initiatives at a recent Forum. 
Silberg first described PCORI’s 
commitment to seeking input from a 
diverse range of stakeholders, including 
patients. Patients and caregivers are 
viewed as a meaningful part of the 
research team and Silberg discussed the 
importance of bringing a broad range of 
voices to the work of PCORI. Silberg 
used the term “research done differently” 
to characterize the way in which PCORI 
strives to shape its purpose. 
Silberg went on to discuss the details of 
the National Priorities for Research and 
the Research Agenda which include: 
assessment of prevention, diagnosis, 
and treatment options; improving 
health care systems; communication 
and dissemination research; addressing 
disparities; and accelerating PCOR and 
methodological research. These priorities 
are intentionally designed to be broad and 
process oriented. 
The PCORI Board of Governors has 
approved a number of pilot projects 
throughout the United States. The projects 
are predominantly population specific, 
and focus on ways of engaging patients in 
research and the dissemination process. 
Examples include a project on how 
physicians and patients talk to one another 
more openly, to a pilot project on the 
use of mobile apps for patient caregiver 
attitudes, behavior, and knowledge, and a 
project on reducing disparities in a rural 
population with multiple cardiovascular 
disease risk factors. 
Throughout his presentation, Silberg 
acknowledged that comparative 
effectiveness research (CER) and PCOR 
are not the easiest topics to communicate 
to the public, but he believes that PCORI 
can build visibility, focus on results and 
lessons learned, and discover powerful 
patient stories that can be shared. 
As Silberg pointed out, “moving the needle” 
requires significant change in researcher 
culture, norms, attitudes, skill, and policies. 
There are multiple influences and constraints 
acting simultaneously on stakeholders and 
researchers. He stressed the importance of 
identifying key stakeholders and the need 
to plan collaborative activities as a way to 
effect change. Silberg explained that change  
will occur slowly and requires a long-term, 
multi-phase/multi-component plan. The 
focus should be on facilitating awareness, 
promoting education and training, 
facilitating feasibility, establishment of 
comprehensive range of incentives and 
rewards. Simply put, “research done 
differently.” 
To listen to Forum podcasts and  
access presentations visit:  
http://jdc.jefferson.edu/hpforum/
numerous challenges in everyday practice, 
particularly for chronically ill, elderly 
patients. For example, warfarin is known to 
have many interactions with other drugs and 
foods, and requires constant monitoring. 
There is a narrow therapeutic range, and 
the blood test monitoring of the INR 
(International Normalized Ratio), can be a 
significant barrier for certain populations as 
well as caregivers. Most significant is that 
warfarin is a leading cause of adverse drug 
events and associated visits to emergency 
rooms, Jackson explained. 
A new group of anti-coagulants, called 
“Novel Oral Anticoagulants” or NOAC, 
including dabigatran, rivaroxiban, and 
apixaban, open the door for promising 
alternatives to warfarin, with fewer 
complexities in the treatment regimens. 
Dr. Jackson offered an overview of the 
major clinical studies, and even indirectly 
compared some of the findings, after 
warning the audience about the dangers of 
indirect comparisons. 
Relating this back to outcomes research, 
Jackson tackled the questions, “what 
treatment works best?” and “are healthcare 
resources well spent?” NOACs, he 
explained, are unique compared to warfarin 
in that they don’t need INR monitoring, 
but as anti-coagulants they still need 
careful oversight. In many key outcomes, 
NOACs were actually superior or better 
than warfarin; however, until real-world 
safety and effectiveness are confirmed, their 
promise of a superior alternative to warfarin 
remains to be seen. He closed by affirming 
that most effective therapies prove cost-
effective, and for the NOACs real-world 
scenarios will be crucial to assess their 
ultimate value. 
Throughout his presentation, Dr. Jackson 
acknowledged the work and expertise of 
Geno J. Merli, MD, Co-Director of the 
Vascular Center at Jefferson, and a national 
expert on anticoagulant therapy. 
For more information visit:  
http://www.theheart.org/columns/clot-blog.do
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Jefferson School of Population Health invites you to join the Grandon Society, a 
membership organization comprised of individuals and organizations focused on advancing 
population health.  Named for our longtime benefactor and champion, Raymond 
C. Grandon, MD, and his wife, Doris, the Grandon Society is designed for leaders 
throughout the healthcare sector who are dedicated to transforming the US health care 
system through collaboration, education and innovation. 
Benefits of membership include exclusive member-only programs and events, a member 
e-newsletter, and early notice and special registration rates for JSPH conferences and events. 
Memberships are available for individuals and for organizations, with special rates for 
academic, non-profit and government institutions. 
For more information or to join the Grandon Society, visit:  
http://www.jefferson.edu/population_health/GrandonSociety.html.
Robert W. Dubois, MD, PhD, Chief Scientific Officer at the National Pharmaceutical Council, responds to questions at recent 
Grandon Society Member-Only workshop.
18   |   POPULATION HEALTH MATTERS
Baghdassarin A, Donaldson R,  
DePiero A, Chernett N, Sule H. 
Knowledge and attitudes assessment of 
out-of hospital emergency physicians in 
Yerevan, Armenia. Poster presented at: 
Consortium of Universities for Global 
Health (CUGH) conference, March 14-
16, 2013,, Washington, DC. 
Berman B. Screening for elder 
maltreatment: an environmental scan of 
the evidence.  Webinar presented at: CMS 
Elder Maltreatment and Care Symposium, 
March 8, 2013, Baltimore, Maryland. 
Chernett N. Beat the blues: a tailored 
depression intervention for African 
American older adults. Presented at: 
Eighth National Conference on Quality 
Health Care for Culturally Diverse 
Populations, Achieving Equity in an Era 
of Innovation and Health System Reform, 
March 13, 2013, Oakland, CA. 
Plumb JD, Brawer RB, Santana A, 
Simmons R, Chernett N. Integrating 
population health into the fabric of 
medical education - College Within the 
College. Poster presented at: Teaching 
Prevention 2013: Developing Educational 
Experiences for and Evolving Healthcare 
System, Association for Prevention 
Teaching and Research (APTR), March 
11, 2013, Washington, DC.  
Simmons R. Plumb J. A global health 
framework based on competencies and 
learning opportunities in graduate  
health education. Presented at: 
Association of Teaching Prevention 
and Research (APTR), March 11, 2013, 
Washington, DC.  
Simmons R. The expanding public health 
profession: career opportunities, dual 
degree programs and how advisors can 
best guide their students. Presented at: 
North East Association of Advisors for 
the Health Professions, April 12, 2013, 
Atlantic City, New Jersey. 
Simmons R, Romney M. Training future 
and current health promotion leaders: 
incorporating policy development and 
advocacy into undergraduate, graduate, 
and continuing education. Presented 
at: Society for Public Health Education 
(SOPHE) Annual Meeting, April 19, 
2013, Orlando, Florida. 
 JSPH Presentations
 JSPH Publications 
Aubry W, Lieberthal RD, Willis A, Bagley 
G, Willis SM, Layton A. Budget impact 
model: epigenetic assay can help avoid 
unnecessary repeated prostate biopsies and 
reduce healthcare spending. Amer Hlth & 




Berman B, Pracilio VP, Crawford 
A, Behm WR, Jacoby R, Nash DB, 
Goldfarb NI. Implementing the physician 
quality reporting system in academic 
multispecialty group practice. Lessons 
learned and policy implications.  AJMQ.  





Berman B. Patient safety in ambulatory 
care: a REAL challenge. Abstract in: Re: 
imagine: A report on the UHC Annual 
Conference 2012. AJMQ. 2013.28 (IS) 
Clancy Z, Keith SW, Rabinowitz C, 
Ceccarelli M, Gagne JJ, Maio V. Statins 
and colorectal cancer risk: a longitudinal 
study. Cancer Causes Control. January 20, 
2013.[Epub ahead of print].
http://link.springer.com.proxy1.lib.tju.edu/
article/10.1007%2Fs10552-013-0160-x
Lieberthal RD, Dudash K, Axelrod R, 
Goldfarb NI. An economic model to value 
companion diagnostics in non-small-cell 
lung cancer. Personalized Medicine. 
2013; 10(2), 139-147. http://www.
futuremedicine.com/doi/abs/10.2217/
pme.13.7?journalCode=pme
Nash DB, Baxter L. Implementing the 
patient-centered medical home model 
for chronic disease care in small medical 
practices: practice group characteristics 
and physician understanding. AJMQ. 
2013;28(2):113-119. 
Nash DB. Technology trends in 
healthcare. Amer Hlth & Drug Benefits. 
2013; 6(1):12-13. 
Nash DB. Zero tolerance for medical 
error? Think again! MedPage Today. 
February 27, 2013. 
Nash DB. Is the doctor on to something? 
MedPage Today. March 27, 2013. 
 
Plumb E, Roe K, Plumb J, Sepe P, Soin 
K, Ramirez A, Baganizi E, Simmons R, 
Khubchandani J. The use of international 
service learning initiatives for global health 
education: case studies from Rwanda and 
Mexico. Health Promotion Practice.  2013; 
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May 8, 2013 
Challenges in Building a Knowledge-
Based Technology Infrastructure for 
Population Health  
Jonathan M. Niloff, MD 
Chief Medical Officer 
MedVentive 
Location: Bluemle Life Sciences Building, Room 101
June 12, 2013 
Managing Population Health in Low to 
Moderate Income Medicare Eligibles
Craig Tanio, MD
Chief Medical Officer 
JenCare 
Location: The Curtis Building, Room 218 
All Forums take place from 8:30 am – 9:30 am 
For more information call: (215) 955-6969 
 Upcoming Jefferson School of Population Health Forums 
Fall 2013 Population Health Forums – SAVE THE DATES
September 11, 2013 
October 9, 2013 
November 13, 2013 
December 11, 2013 
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